Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tripeptide interference with human immunodeficiency virus type 1 morphogenesis.

Stefan Höglund1, Jin Su, Sara Sandin Reneby

  • 1Department of Biochemistry, Biomedical Center, Uppsala University, Uppsala, Sweden. Stefan.Hoglund@biokem.uu.se

Antimicrobial Agents and Chemotherapy
|October 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pro-regenerative fingerprints identified in a sub-population of adult mouse cardiomyocytes by integrative single-cell proteomics.

Genome biology·2026
Same author

Small molecule inhibition of voltage dependent anion channel 1 reroutes mitochondrial metabolite flux.

Molecules and cells·2026
Same author

MitoSAM-dependent lipoylation controls postnatal heart development via metabolic remodeling.

bioRxiv : the preprint server for biology·2026
Same author

Klebsiella pneumoniae LPS drives stromal-mediated repression of p53 and colorectal cancer chemoresistance.

Cell death & disease·2026
Same author

Investigating performance and key factors for real-world deployment of grain image classification using convolutional neural networks.

Scientific reports·2026
Same author

ISG15-USP18 signaling restrains viperin-dependent metabolic antiviral restriction.

bioRxiv : the preprint server for biology·2026

Tripeptide amides targeting the human immunodeficiency virus type 1 (HIV-1) capsid protein p24 show significant antiviral activity. These compounds disrupt HIV-1 replication and assembly, offering a potential new therapeutic strategy.

Area of Science:

  • Virology
  • Molecular Biology
  • Drug Discovery

Background:

  • Viral capsid assembly is a key target for antiviral therapies.
  • The Gag polyprotein forms retroviral particles, including the capsid protein p24 in HIV-1.

Purpose of the Study:

  • To identify novel compounds that inhibit HIV-1 replication.
  • To investigate the potential of tripeptide amides derived from the HIV-1 capsid protein p24 sequence as antiviral agents.

Main Methods:

  • Screening of 83 tripeptide amides against HIV-1 replication.
  • Electron microscopy to visualize viral particle structure.
  • Assessing interaction between tripeptides and the p24 capsid protein.

Main Results:

Related Experiment Videos

  • Seven of 83 tripeptide amides suppressed HIV-1 replication by over 80% at 100 micro M.
  • Glycyl-prolyl-glycine-amide (GPG-NH(2)), alanyl-leucyl-glycine-amide (ALG-NH(2)), and arginyl-glutaminyl-glycine-amide (RQG-NH(2)) were the most potent.
  • Electron microscopy revealed disarranged core structures and potential budding arrest in treated HIV-1 progeny.
  • Nonamidated tripeptide controls lacked biological activity and did not interact with p24.

    • Conclusions:

    • Tripeptide amides targeting the HIV-1 capsid protein p24 demonstrate potent antiviral activity.
    • These compounds interfere with viral assembly and budding, suggesting a novel therapeutic mechanism.
    • The amidation of the carboxyl terminus is crucial for biological activity and interaction with p24.